Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

At interim analysis, progression-free survival was significantly prolonged for camrelizumab and chemotherapy vs chemotherapy alone (n=419; median 11.3 vs 8.3 months; HR for progression or death 0·60; p=0·0001) although with higher incidence of serious adverse events (36% vs 13%).

Source:

The Lancet Respiratory Medicine